Equities research analysts expect that Danaher Corporation (NYSE:DHR) will post sales of $4.46 billion for the current quarter, according to Zacks. Eight analysts have issued estimates for Danaher Corporation’s earnings, with the highest sales estimate coming in at $4.53 billion and the lowest estimate coming in at $4.39 billion. Danaher Corporation reported sales of $4.13 billion during the same quarter last year, which indicates a positive year over year growth rate of 8%. The firm is scheduled to announce its next quarterly earnings report on Thursday, October 19th.

According to Zacks, analysts expect that Danaher Corporation will report full-year sales of $4.46 billion for the current financial year, with estimates ranging from $17.92 billion to $18.15 billion. For the next fiscal year, analysts expect that the firm will post sales of $18.79 billion per share, with estimates ranging from $18.64 billion to $18.94 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that that provide coverage for Danaher Corporation.

Danaher Corporation (NYSE:DHR) last released its quarterly earnings data on Thursday, July 20th. The conglomerate reported $0.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $0.02. The firm had revenue of $4.51 billion for the quarter, compared to analyst estimates of $4.50 billion. Danaher Corporation had a return on equity of 11.15% and a net margin of 12.63%. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.90 earnings per share.

Several equities research analysts recently issued reports on DHR shares. Credit Suisse Group restated a “buy” rating and issued a $93.00 target price on shares of Danaher Corporation in a report on Wednesday, May 24th. Janney Montgomery Scott cut shares of Danaher Corporation from a “buy” rating to a “neutral” rating in a report on Wednesday, June 7th. BidaskClub cut shares of Danaher Corporation from a “hold” rating to a “sell” rating in a report on Thursday, June 15th. Zacks Investment Research cut shares of Danaher Corporation from a “hold” rating to a “sell” rating in a report on Monday, June 19th. Finally, Deutsche Bank AG restated a “buy” rating and issued a $97.00 target price on shares of Danaher Corporation in a report on Wednesday, June 21st. One analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Danaher Corporation has a consensus rating of “Buy” and a consensus target price of $91.76.

Shares of Danaher Corporation (NYSE DHR) opened at 82.16 on Friday. Danaher Corporation has a 1-year low of $75.71 and a 1-year high of $88.01. The firm has a 50-day moving average price of $82.08 and a 200 day moving average price of $84.16. The company has a market cap of $57.08 billion, a price-to-earnings ratio of 26.22 and a beta of 1.03.

COPYRIGHT VIOLATION WARNING: This piece was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://theolympiareport.com/2017/08/27/analysts-expect-danaher-corporation-dhr-will-post-quarterly-sales-of-4-46-billion.html.

In related news, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of the firm’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $81.78, for a total transaction of $799,154.16. Following the completion of the transaction, the insider now directly owns 155,520 shares of the company’s stock, valued at $12,718,425.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Linda P. Hefner sold 10,578 shares of the firm’s stock in a transaction on Friday, July 21st. The shares were sold at an average price of $83.03, for a total transaction of $878,291.34. Following the transaction, the director now directly owns 42,151 shares of the company’s stock, valued at $3,499,797.53. The disclosure for this sale can be found here. Insiders have sold 27,808 shares of company stock valued at $2,296,236 over the last ninety days. 12.20% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of DHR. GQG Partners LLC bought a new position in Danaher Corporation during the second quarter valued at $101,000. Peddock Capital Advisors LLC boosted its position in shares of Danaher Corporation by 17.4% in the first quarter. Peddock Capital Advisors LLC now owns 1,224 shares of the conglomerate’s stock worth $105,000 after buying an additional 181 shares during the last quarter. Proficio Capital Partners LLC boosted its position in shares of Danaher Corporation by 92.3% in the first quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock worth $105,000 after buying an additional 598 shares during the last quarter. Monetary Management Group Inc. boosted its position in shares of Danaher Corporation by 10.7% in the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after buying an additional 150 shares during the last quarter. Finally, Acrospire Investment Management LLC boosted its position in shares of Danaher Corporation by 185.5% in the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after buying an additional 1,100 shares during the last quarter. 76.12% of the stock is owned by institutional investors.

Danaher Corporation Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Get a free copy of the Zacks research report on Danaher Corporation (DHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Danaher Corporation (NYSE:DHR)

Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.